Track market-moving stories before they get noisy

Tempus AI (TEM - Free Report) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.

The earnings report, which is expected to be released on July 30, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.

While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise.

Zacks Consensus EstimateThis health care technology company is expected to post quarterly loss of $0.12 per share in its upcoming report, which represents a year-over-year change of +45.5%.

Revenues are expected to be $381.58 million, up 21.3% from the year-ago quarter.

Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 3.59% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.

Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts.

Price, Consensus and EPS Surprise

Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.

A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.

Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).

How Have the Numbers Shaped Up for Tempus?For Tempus, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +21.74%.

On the other hand, the stock currently carries a Zacks Rank of #3.

So, this combination indicates that Tempus will most likely beat the consensus EPS estimate.

Does Earnings Surprise History Hold Any Clue?Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.

For the last reported quarter, it was expected that Tempus would post a loss of$0.21 per share when it actually produced a loss of -$0.13, delivering a surprise of +38.10%.

Over the last four quarters, the company has beaten consensus EPS estimates three times.

Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.

That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

Tempus appears a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.

Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.

Posted by Defense World Staff on Jul 22nd, 2026

Tempus AI (NASDAQ:TEM) executives said the company’s planned acquisition of Personalis is intended to strengthen its position in minimal residual disease, or MRD, testing, while expanding its biopharma data and profiling capabilities.

On a call with analysts, Tempus said it agreed to acquire all outstanding shares of Personalis not already owned by Tempus at $16.25 per share. The company said the price represents a 6% premium to Personalis’ Friday closing price and a 28% premium to its unaffected 30-day volume-weighted average price.

The consideration is structured as 100% stock, though Tempus has the option to pay up to 50% in cash. Personalis shareholders would receive a floating exchange ratio of Tempus common stock for each Personalis share held at closing, subject to a maximum exchange ratio of 0.3356. Tempus said any cash portion could be financed with cash on hand and additional borrowing procured between signing and closing. The companies expect the transaction to close in late 2026 or early 2027.

Tempus Points to MRD Growth and Reimbursement Momentum Tempus said Personalis’ NeXT Personal offering has seen strong adoption, with quarter-over-quarter growth of 38%. The company said volumes could become “even more material and higher” as additional sales representatives are equipped to sell the offering and as more indications secure reimbursement.

In response to a question from Kallum Titchmarsh of Morgan Stanley, an executive identified as Eric said Tempus is “quickly gaining market adoption,” citing both overall growth in the MRD market and the performance of Personalis’ assay. He said Tempus expects to embed more of its technology into the MRD offering over time, including hospital connectivity, AI-enabled ordering tools and AI-derived insights.

Eric said Tempus has so far been selective in allowing its sales force to carry the MRD product, with roughly 10% of sales representatives currently involved. He said the company expects to expand that access as more indications receive reimbursement.

Why Tempus Says the Timing Is Right Asked by Kyle Mikson of Canaccord Genuity why Tempus is pursuing the acquisition now, Eric said the company had reviewed Personalis in 2023 but opted at that time for a commercial agreement because Personalis still faced several years of heavy investment. He said Personalis has since advanced the assay and is entering a phase in which coverage and reimbursement should improve the economics of the tests.

Eric said MRD assays can move from generating little or no revenue in certain uses to producing significant revenue after analytic validity, clinical validity, publication and MolDX approval requirements are met. He said Personalis is now entering that part of the cycle, and Tempus expects its financial profile to improve.

Jim Rogers, CFO and Treasurer of Tempus AI, said the company’s core business has “good tailwinds” from therapy selection volume growth and average selling price improvements. He said Tempus is generating incremental gross profit dollars and had already intended to reinvest a portion of that into the business, with MRD as a major investment area.

Data and Biopharma Opportunities Tempus said the Personalis portfolio also enhances its biopharma offering through profiling and immuno-oncology capabilities. The company highlighted the potential value of de-identified longitudinal MRD data, saying serial measurements can reveal disease dynamics, treatment response, resistance and recurrence, which may support biomarker discovery, patient selection and trial optimization.

Eric said the prior relationship between the companies gave Tempus broad clinical distribution rights, while Personalis retained its own biopharma business and data rights. After closing, he said Tempus expects to more tightly combine those capabilities, which he said could be “catalytic” to both companies’ pharma businesses.

Rogers added that Tempus already has a large biopharma data business and does sequencing for biopharma customers. He said integrating Personalis’ biopharma business with Tempus’ current offering could help expand overall relationships with biopharma clients.

Financial Targets Remain in Place Tempus said it will provide more detail on the transaction’s financial impact and outlook during its second-quarter earnings call on July 30. Despite the acquisition, the company said it intends to be adjusted EBITDA and free cash flow positive in 2027.

Asked about margins and reimbursement by Mark Massaro of BTIG, Eric said Tempus was not ready to provide extensive detail on Personalis’ business before a future update, but said Personalis is collecting clinical-side reimbursement dollars. He added that Tempus would not have agreed to the acquisition if it did not believe the margin profile would become “super healthy.”

Elizabeth Krutoholow, Tempus AI’s Vice President of Investor Relations, closed the call by thanking participants and said the company expects to speak with investors again on its July 30 second-quarter call.

About Tempus AI (NASDAQ:TEM) Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.

« PREVIOUS HEADLINEBank Stocks To Add to Your Watchlist – July 20th

NEXT HEADLINE »Best Mining Stocks To Add to Your Watchlist – July 20th

Tempus AI shares erased early losses and recovered after an initial selloff tied to the company’s acquisition of Personalis.

Tempus AI Targets $20 Billion MRD MarketThe acquisition, valued at $1.5 billion, is set to expand Tempus’ reach in the MRD market. Tempus claims it presents a $20 billion opportunity.

William Blair has a favorable view of the strategic fit and expects Personalis’ growth and profitability trajectory to be meaningfully different inside of Tempus than it would have been as a standalone company.

William Blair Sees Long-Term Growth But Flags Profitability QuestionsThe acquisition multiple is high at ~14 times 2027 consensus sales, though analyst Matt Larew wrote that the consensus likely understates Personalis’ 2027 revenue outlook given recent MolDX approvals and Tempus’ ability to further leverage its commercial infrastructure.

The other pressure point will be profitability given Personalis’ clear loss-making position (consensus adjusted EBITDA of -$90 million for 2027) and Tempus’s commitment to be EBITDA and FCF positive in 2027.

Management argued that the timing of the acquisition is coincident with Personalis reaching an inflection point, with several years of commercial and reimbursement investment likely to yield enhanced ASPs and margins moving forward.

William Blair rates Tempus AI shares Market Perform. For multiple expansion to materialize, analyst Larew expects investors will want to see additional positive proof points on recent M&A contributing to numbers and more clarity on the growth profile and durability of the data business.

BNP Paribas Says Deal Could Increase Pressure On NateraAnalyst Navann Ty wrote that Natera maintains a defensible, leadership position in the space, with a solid pipeline of ongoing clinical trials.

BNP Paribas maintains Neutral on Natera as the company continues to progress towards catalysts but views the current valuation as fair.

TEM Stock Price Activity: Tempus AI shares were up 1.96% at $49.36 at the time of publication on Tuesday, according to Benzinga Pro data.

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

The selloff has made one of Cathie Wood‘s highest-conviction holdings considerably cheaper. The question now is whether the decline represents a buying opportunity—or a warning sign.

Cathie Wood and Wall Street Still BelieveWall Street also remains firmly bullish.

According to consensus estimates from 19 analysts, Tempus carries an average price target of $66.50, implying roughly 37% upside from current levels. The three most recent analyst updates—from Guggenheim, Freedom Capital Markets and Needham—average $66.33, suggesting analysts have yet to meaningfully lower expectations despite the recent pullback.

That suggests the market’s reaction is centered more on the timing and structure of the Personalis acquisition than on Tempus’ long-term AI and precision medicine strategy.

TEM Stock Chart Says Something DifferentChart created using Benzinga Pro

The technical picture, however, has deteriorated.

Tempus shares are now trading below their eight-day, 20-day and 50-day simple moving averages, a sign that short- and intermediate-term momentum has turned negative.

The stock’s MACD (moving average convergence/divergence) has produced a bearish crossover, with the histogram continuing to weaken, indicating downside momentum remains in control.

Meanwhile, the Relative Strength Index (RSI) has slipped to around 40. While the reading isn’t yet in oversold territory, it suggests buying momentum has faded considerably as sellers continue to dominate trading.

Taken together, the chart suggests investors may not yet be finished digesting the recent selloff.

So, Should Investors Buy the Dip?The answer depends on which signal investors trust more.

Fundamentally, Tempus still enjoys strong support from both Wall Street analysts and Cathie Wood, whose flagship ETF continues to maintain the company as one of its largest positions. The Personalis acquisition also strengthens Tempus’s leadership in AI-powered precision oncology, even if investors are questioning the near-term impact of issuing stock to finance the deal.

Technically, however, the picture remains far less encouraging. Momentum indicators continue to point lower, and the stock has yet to show signs that buyers are stepping back in.

For investors looking to initiate or add to a position, the coming earnings report on July 30 could become the next major catalyst. Strong results—or a clearer roadmap for integrating Personalis while improving margins—could validate Wall Street’s optimism.

Until then, Tempus presents investors with a familiar dilemma: a company that analysts continue to like, a high-profile backer that hasn’t wavered, and a chart that still says patience may be the better trade.

Image via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

Tempus AI, a healthcare tech company, is a favorite of investor Cathie Wood. Personalis does cancer testing.

Store

SubscribeSign In

My Subscriptions

Founder's ClubSwingTraderLeaderboardMarketSurgeeIBDIBD DigitalIBD LiveCustomer Center

My Stock Lists

Email Preferences

Help & Support

Sign Out

Search stocks or keywords

Sections

My IBD

MARKET TREND

STOCK LISTS

STOCK RESEARCH

NEWSECONOMY

VIDEOS & PODCASTS

HOW TO INVESTEDUCATIONAL RESOURCESStoreMy Products

Founder's ClubSwingTraderLeaderboardMarketSurgeeIBDIBD DigitalIBD Live

Recently Searched

Stock Market Week Ahead: Navigating Uncertainty

These 7 Stocks Are Analyst Favorites For Magnificent Earnings Growth; Google Holds Top Rating

ASML, Snowflake Lead Five Stocks Near Buy Points In Tough Market Tempus AI (TEM) pledged to buy cancer diagnostics outfit Personalis (PSNL) for $1.5 billion on Monday. But shares of both medtech companies skidded. The deal follows a rumor last week that Merck (MRK) and others, including potentially Tempus AI, had expressed interest in buying Personalis. Personalis makes a blood test called NeXT Personal that screens for circulating tumor DNA, a…

Copyright ©2026 Investor's Business Daily, LLC. All rights reserved. 87990cbe856818d5eddac44c7b1cdeb8

MarketBeat Week in Review – 02/23 - 02/27Tempus AI NASDAQ: TEM executives said the company’s planned acquisition of Personalis is intended to strengthen its position in minimal residual disease, or MRD, testing, while expanding its biopharma data and profiling capabilities.

On a call with analysts, Tempus said it agreed to acquire all outstanding shares of Personalis not already owned by Tempus at $16.25 per share. The company said the price represents a 6% premium to Personalis’ Friday closing price and a 28% premium to its unaffected 30-day volume-weighted average price.

Get Tempus AI alerts:

After a Near 50% Drop, Tempus AI Could Be Ripe for a ReboundThe consideration is structured as 100% stock, though Tempus has the option to pay up to 50% in cash. Personalis shareholders would receive a floating exchange ratio of Tempus common stock for each Personalis share held at closing, subject to a maximum exchange ratio of 0.3356. Tempus said any cash portion could be financed with cash on hand and additional borrowing procured between signing and closing. The companies expect the transaction to close in late 2026 or early 2027.

Tempus Points to MRD Growth and Reimbursement Momentum Tempus said Personalis’ NeXT Personal offering has seen strong adoption, with quarter-over-quarter growth of 38%. The company said volumes could become “even more material and higher” as additional sales representatives are equipped to sell the offering and as more indications secure reimbursement.

Tempus AI Sold Off After a Beat—But the Rebound Case Is BuildingIn response to a question from Kallum Titchmarsh of Morgan Stanley, an executive identified as Eric said Tempus is “quickly gaining market adoption,” citing both overall growth in the MRD market and the performance of Personalis’ assay. He said Tempus expects to embed more of its technology into the MRD offering over time, including hospital connectivity, AI-enabled ordering tools and AI-derived insights.

Eric said Tempus has so far been selective in allowing its sales force to carry the MRD product, with roughly 10% of sales representatives currently involved. He said the company expects to expand that access as more indications receive reimbursement.

Why Tempus Says the Timing Is Right Asked by Kyle Mikson of Canaccord Genuity why Tempus is pursuing the acquisition now, Eric said the company had reviewed Personalis in 2023 but opted at that time for a commercial agreement because Personalis still faced several years of heavy investment. He said Personalis has since advanced the assay and is entering a phase in which coverage and reimbursement should improve the economics of the tests.

Eric said MRD assays can move from generating little or no revenue in certain uses to producing significant revenue after analytic validity, clinical validity, publication and MolDX approval requirements are met. He said Personalis is now entering that part of the cycle, and Tempus expects its financial profile to improve.

Jim Rogers, CFO and Treasurer of Tempus AI, said the company’s core business has “good tailwinds” from therapy selection volume growth and average selling price improvements. He said Tempus is generating incremental gross profit dollars and had already intended to reinvest a portion of that into the business, with MRD as a major investment area.

Data and Biopharma Opportunities Tempus said the Personalis portfolio also enhances its biopharma offering through profiling and immuno-oncology capabilities. The company highlighted the potential value of de-identified longitudinal MRD data, saying serial measurements can reveal disease dynamics, treatment response, resistance and recurrence, which may support biomarker discovery, patient selection and trial optimization.

Eric said the prior relationship between the companies gave Tempus broad clinical distribution rights, while Personalis retained its own biopharma business and data rights. After closing, he said Tempus expects to more tightly combine those capabilities, which he said could be “catalytic” to both companies’ pharma businesses.

Rogers added that Tempus already has a large biopharma data business and does sequencing for biopharma customers. He said integrating Personalis’ biopharma business with Tempus’ current offering could help expand overall relationships with biopharma clients.

Financial Targets Remain in Place Tempus said it will provide more detail on the transaction’s financial impact and outlook during its second-quarter earnings call on July 30. Despite the acquisition, the company said it intends to be adjusted EBITDA and free cash flow positive in 2027.

Asked about margins and reimbursement by Mark Massaro of BTIG, Eric said Tempus was not ready to provide extensive detail on Personalis’ business before a future update, but said Personalis is collecting clinical-side reimbursement dollars. He added that Tempus would not have agreed to the acquisition if it did not believe the margin profile would become “super healthy.”

Elizabeth Krutoholow, Tempus AI’s Vice President of Investor Relations, closed the call by thanking participants and said the company expects to speak with investors again on its July 30 second-quarter call.

About Tempus AI (NASDAQ:TEM)Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company's core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Tempus AI Right Now?Before you consider Tempus AI, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tempus AI wasn't on the list.

While Tempus AI currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Obchodní aktivita amerických politiků je investory dlouhodobě bedlivě sledovaná. V minulých letech byly pod drobnohledem především investiční kroky bývalé šéfky Sněmovny reprezentantů Nancy Pelosiové (a jejího manžela), od návratu Donalda Trumpa do Bílého domu se pak více pozornosti upřelo právě na něj. Americký prezident v posledním majetkovém přiznání zveřejnil tisíce transakcí uskutečněných prostřednictvím svěřenského fondu. Server Benzinga se podíval na portfolia obou politiků a našel v nich hned desítku shodných titulů.

Společným jmenovatelem většiny shodných pozic jsou technologické firmy a společnosti profitující z rozvoje umělé inteligence. Na seznamu tak figurují jak zástupci Magnificent Seven, tak ale třeba i méně tradiční sázky typu Tempus AI či energetická skupina Vistra.

Mezi nejčerstvějšími přírůstky v portfoliu rodiny Pelosiových jsou Uber a Intel. Paul Pelosi podle zveřejněných dokumentů nakoupil dlouhodobé call opce na obě společnosti s expirací v příštím roce. Trumpův svěřenský fond mezitím letos u obou titulů vykázal kombinaci nákupů i prodejů, přičemž převažovaly nákupní transakce.

Výrazný překryv pak lze zpozorovat u největších technologických společností. Pelosiovi dlouhodobě drží expozici vůči Alphabetu, Nvidii, Applu, Amazonu a Broadcomu, často prostřednictvím opcí, které byly následně převedeny na akcie. Trumpův fond zase během letoška uskutečnil u těchto jmen desítky obchodů, přičemž některé transakce byly v řádu milionů dolarů.

Zvláštní pozornost pak poutá Nvidia, která se stala jedním z hlavních symbolů boomu umělé inteligence. Pelosiovi v posledních letech opakovaně navyšovali svou expozici vůči nejhodnotnější veřejně obchodované společnosti na světě, zatímco Trumpův fond patří mezi nejaktivnější obchodníky s tímto titulem, odhalila analýza serveru Benzinga.

Kromě zavedených technologických gigantů spojuje obě portfolia také orientace na perspektivní segmenty. Zde můžeme zařadit Tempus AI, jež využívá umělou inteligenci ve zdravotnictví, nebo velkého hráče v oblasti kybernetické bezpečnosti Palo Alto Networks. Dalším méně očekávaným jménem je pak energetická společnost Vistra, kterou investoři často vnímají jako nepřímou sázku na rostoucí spotřebu elektřiny datových center.

Deset akcií, které se letos objevily v portfoliích Pelosiové a Trumpa:

Uber Technologies
Intel
Alphabet
Nvidia
Tempus AI
Vistra
Apple
Amazon
Broadcom
Palo Alto Networks

Odlišné investiční přístupy

Benzinga si také všímá toho, že i přes shodu u některých titulů se styl obou táborů výrazně liší. Paul Pelosi je známý využíváním dlouhodobých call opcí, které následně převádí na akcie. Jeho strategie se soustředí především na velké technologické společnosti a strukturální růstové trendy.

To Trumpův svěřenský fond naopak podle zveřejněných údajů realizoval během let 2025 a 2026 desetitisíce transakcí napříč řadou sektorů. Přesto i zde dominují velké americké společnosti a zejména technologické tituly, které tvoří významnou část nejaktivněji obchodovaných pozic.

755 Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in TEM over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

5.45K Followers

Analyst’s Disclosure: I/we have a beneficial long position in the shares of TEM either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

TEM weekly chart shows potential double bottom near 78.6% Fibonacci retracement zone In addition, a downtrend line across recent highs that was again confirmed on Tuesday as a resistance area. Since the line was touched or almost touched more than several times, including today, it suggests that a decisive breakout of the pattern may initially be indicated on a move above that line. However, the lower swing high of $54.75 provides a horizontal level to signal an upside breakout. Tuesday’s breakout failed to confirm with a closing price below the top boundary line.

Tuesday’s Missed Breakout and Momentum Shift The 100-day moving average is near $51.55 currently and the low for Tuesday was $51.18. That means most of Tuesday’s trading range held above the 100-day moving average for the first time since it broke below it as support on November 6. This is a sign of improving short-term bullish momentum. Moreover, with TEM now poised for a possible upside breakout, major moving averages are aligned below price and are providing trend support.

Breakout Level and Recovery Target A decisive breakout above $54.75 may signal the next leg of recovery for TEM. An initial target is near the 200-day moving average at $64.54, but a confirmed trend reversal signal would suggest that the 200-day moving average could be reclaimed given the long-term nature of the current bottoming pattern.

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of the PRECISION Challenge, a national initiative engineered to accelerate the next generation of oncology breakthroughs leveraging its foundational model. The PRECISION Challenge aims to unlock breakthroughs in oncology at scale by providing access to data, funding, and expertise to multidisciplinary teams around the world who seek t.

Tempus Introduces 'Preview': Bridging the Critical Time Gap Between Diagnostic Order and Definitive Results Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the introduction of Tempus Preview, an application providing rapid, clinically significant insights that close the gap between the time of order and delivery of insights. Representing a significant paradigm shift in precision oncology workflows, Tempus Preview offers preliminary results in the critical window between when a diagnostic test is ordered and when final sequencing results are delivered by surfacing key mutation predictions within approximately 24 hours of tissue receipt.

The initial days following an advanced cancer diagnosis are critical for strategic treatment planning, yet clinicians have traditionally been forced to operate in an information vacuum while awaiting comprehensive genomic profiling results. Tempus Preview fundamentally redefines this diagnostic timeline. By combining Tempus’ multimodal data and advanced AI capabilities applied directly to the earliest touchpoints of the laboratory workflow, Tempus equips care teams to access early, clinically significant, information that can help inform complex decisions for patients and shorten the time between receipt of final molecular results and implementation of a personalized treatment plan.

At launch, Tempus Preview will focus exclusively on high-impact biomarkers where early insights can be critical, including:

Surfacing patients more likely to harbor microsatellite instability (MSI-H), a biomarker linked to improved response to immune checkpoint inhibitors and potential hereditary risk factors, in colorectal, endometrial, prostate, and esophagogastric cancers. Predicting EGFR mutations in non-small cell lung cancer (NSCLC), a biomarker that infers response to targeted therapy, but often lacks response to frontline immunotherapy. Highlighting increased probability of potential rare, yet clinically significant FGFR fusions in hepatobiliary and bladder cancers, that may indicate potential response to targeted therapy and improved patient prognosis if gene fusions are present. Shortly thereafter, Tempus Preview will expand to other critical biomarkers.

Tempus Preview’s biomarker predictions are powered by Paige Predict, an advanced AI model that analyzes standard H&E images to provide genomic insights. Paige Predict, trained on millions of slides, has been validated for clinical use as part of Tempus’ laboratory-developed test.

“At Tempus, our unique combination of a diagnostic lab and an advanced data platform enables us to build AI models powered by our unparalleled depth of real-world data,” said Eric Lefkofsky, Founder and CEO of Tempus. “That foundation creates a powerful flywheel: every insight strengthens our models, and every model helps generate more clinically meaningful insights for providers and patients. Tempus Preview brings this intelligence directly into the clinical workflow, delivering early, clinically relevant information within one day of sample receipt, which for many patients can mean the difference in how they are treated. This is our AI flywheel in action: transforming complex information into timely insights, delivered to physicians when they need them most.”

Additional details on Tempus Preview can be found here.

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus’ industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding potential impact of Tempus Preview. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.

You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: the intended use of Tempus’ products and services; Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on February 24, 2026, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260530829355/en/

Tempus Unveils the Next-Generation of Lens, Expanding its Agentic AI Platform for Oncology Drug Development Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of the next-generation of Lens, its pioneering agentic AI platform designed to accelerate drug development and research. This evolution seamlessly connects Tempus’ multimodal data, AI tooling and computational infrastructure to deliver actionable insights at the pace required for drug development.

The next-generation of the Lens platform is built on over a decade of longitudinal real-world data and years of expertise translating that data into actionable evidence for biopharma. Lens combines one of the world's largest real-world multimodal datasets, high-performance AI computing, Tempus’ oncology foundation models, validated AI agents, and scientific workflows, all integrated into a single platform.

The platform was purpose-built to enable drug development teams to design better clinical trials, target patient subgroups faster, and generate critical evidence in a fraction of the time. Lens is commercially available today via lens.tempus.ai and is already utilized by a rapidly expanding user base, including 19 of the top 20 largest biopharma companies.

The multi-agent platform is designed to deliver a seamless, end-to-end experience through several specialized tools:

Custom Research Plan Generation: Lens Co-scientist agents have deep context on the Tempus RWD model and datasets available within a project, and are grounded in oncology knowledge for insight generation. Users can propose complex biological hypotheses using plain language and receive a targeted analysis plan that can be refined seamlessly by collaborating directly with the agent. On-Demand Execution: Once a plan is finalized, the agent executes the analysis in code against Tempus’ massive multimodal library—including more than 8.5 million queryable de-identified patient records—to deliver robust, code-backed results in minutes. Specialized AI Agents: Custom-validated agents designed to support common use cases of real-world data, such as biomarker validation and trial design support agents, are optimized for specific phases of drug development and translational workflows. Reproducible Intelligence: Results are delivered via interactive, shareable applications and reports. For deep validation and full transparency, users can instantly toggle to a “code” view to audit the underlying analytical logic or export the entire project to a private Workspace for further technical extension. "Drug development requires thousands of pivotal decisions between molecule and approval, and at its core, it is a navigation problem—most paths end in dead studies and wasted capital, which is why the industry needs a fundamentally different approach," said Ryan Fukushima, CEO of Data and Apps at Tempus. "Real-world multimodal data is complex, and turning it into decisions has historically required too much domain and data science expertise, resulting in weeks or months of manual analysis. The next generation of Lens consolidates this workflow into a single platform, with Tempus One serving as a co-scientist that does much of the heavy lifting. We've tuned every layer of the platform to empower biopharma teams to see the optimal development path clearly and make critical decisions faster than ever before."

For more information, including how to access Lens, please visit: lens.tempus.ai.

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus’ industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding expected outcomes and benefits of Lens, including but not limited to features designed to accelerate drug development and research. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.

You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: the intended use of Tempus’ products and services; Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on February 24, 2026, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260531652876/en/

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the upcoming clinical availability of xH, a next-generation sequencing (NGS) test that uses a whole-genome sequencing (WGS) approach for the detection of actionable oncologic targets in peripheral blood and bone marrow samples from patients with hematologic malignancies. Tempus first announced the xH assay for research use only in January 2025.

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, Yale New Haven Hospital (YNHH) and Memorial Sloan Kettering Cancer Center (MSK) today announced the launch of a digital pathology IMS Open-Source Consortium (“IMS Consortium”). Designed to accelerate the democratization and standardization of digital pathology, the consortium aims to bring together leading academic medical centers and industry partners to devel.

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that it will participate in the Goldman Sachs 47th Annual Global Healthcare Conference. Tempus Founder and CEO Eric Lefkofsky will participate in a fireside chat at 2:00 p.m. ET on Monday, June 8. A live webcast of the conversation will be available here. About Tempus Tempus is a technology company advancing precision medicine through the practi.

Tempus AI, Inc. (TEM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

HomeStock IdeasLong IdeasHealthcare 

SummaryTempus AI is rated Strong Buy, leveraging a unique data moat and network effect in healthcare AI.TEM's Diagnostics and Data & Applications segments drive robust 36% YoY revenue growth, with expanding gross margins and deepening pharma partnerships.Massive proprietary datasets (45M+ de-identified records, 500+ PB) underpin AI tools, SaaS revenue, and cross-selling opportunities, creating high barriers to entry.Key risks include continued unprofitability, $1.3B debt, high short interest (20%), and regulatory sensitivity, but profitability and AI adoption could trigger a short squeeze. Tom Werner/DigitalVision via Getty Images

Investment Thesis Tempus AI, Inc. (TEM) stock is down 20% YTD, and I believe this is a gift that the market rarely gives.

In this article, I’m trying to explain why the company has a

1.45K Followers

Analyst’s Disclosure: I/we have a beneficial long position in the shares of TEM either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced publication of successful multi-site validation of its software, which received U.S. Food and Drug Administration clearance in 2024 for predicting the one-year risk of atrial fibrillation or flutter (AF). The study, titled "Multi-Center Validation of an Artificial Intelligence-Enabled ECG Model to Predict 1-Year Risk of Atrial Fibrillation or Fl.